Our Biosimilars Pipeline
We are developing biosimilar compounds for the treatment of autoimmune and oncology indications. We currently have 2 biosimilar candidates in late phase of clinical development, while future pipeline projects are in pre-clinical development.
| Compound | Clinical phase | Key Indications | Mode of action | More information |
|---|---|---|---|---|
| BI 695501 (adalimumab biosimilar candidate) |
approved | Rheumatoid arthritis, Psoriasis, Inflammatory Bowel Disease | Anti-Tumor Necrosis Factor-alpha (TNFa) | For more information click here |
| BI 695502 (bevacizumab biosimilar candidate) |
Phase III | Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), metastatic Colorectal Cancer | Vascular Endothelial Growth Factor (VEGF) inhibition | For more information click here |